Sort   by:  
 Page size 
UnknownPhase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer.
Not available
S-EPMC3574268 | biostudies-literature
UnknownPhase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma.
Not available
S-EPMC6804828 | biostudies-literature
UnknownPrevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer.
Not available
S-EPMC3753703 | biostudies-literature
UnknownIntravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study.
Not available
S-EPMC5648171 | biostudies-literature
UnknownPhase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.
Not available
S-EPMC3778101 | biostudies-literature
UnknownEV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma.
Not available
S-EPMC7106979 | biostudies-literature
UnknownGenome sequencing identifies a basis for everolimus sensitivity.
Not available
S-EPMC3633467 | biostudies-literature
UnknownEnfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer.
Not available
S-EPMC10852367 | biostudies-literature
UnknownSafety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors.
Not available
S-EPMC11032703 | biostudies-literature
Sort   by:  
 Page size